Symbol="IOVA"
AssetType="Common Stock"
Name="Iovance Biotherapeutics Inc"
Description="Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company is headquartered in San Carlos, California."
CIK="1425205"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="999 SKYWAY ROAD, SUITE 150, SAN CARLOS, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="1625011000"
EBITDA="-407744000"
PERatio="None"
PEGRatio="0"
BookValue="2.972"
DividendPerShare="0"
DividendYield="0"
EPS="-2.22"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.342"
ReturnOnEquityTTM="-0.675"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-2.22"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="24.55"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="2.774"
EVToRevenue="-"
EVToEBITDA="-2.187"
Beta="0.0926"
num_52WeekHigh="13.44"
num_52WeekLow="5.28"
num_50DayMovingAverage="7.57"
num_200DayMovingAverage="7.42"
SharesOutstanding="224449000"
DividendDate="None"
ExDividendDate="None"
symbol="IOVA"
open="6.80"
high="7.28"
low="6.80"
price="7.24"
volume="5831700.00"
latest_trading_day="2023-07-07"
previous_close="6.81"
change="0.43"
change_percent="6.3142%"
aroon_positive_momentum_days="68"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="68"
Volume_recent_avg="4627058"
Change_recent_avg="-0.03"
Delta_recent_avg="0.41"
Variance_recent_avg="0.21"
Change_ratio_recent_avg="-0.54"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="68"
Aroon_momentum_negative="32"
image_negative_thumbnail_id_1="164"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0012.jpeg"
image_negative_thumbnail_id_2="1118"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0151.jpeg"
image_neutral_thumbnail_id_1="583"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0016.jpeg"
image_neutral_thumbnail_id_2="588"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0011.jpeg"
image_positive_thumbnail_id_1="664"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0044.jpeg"
image_positive_thumbnail_id_2="966"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0128.jpeg"
image_professor_thumbnail_id_1="1175"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0009.jpeg"
image_professor_thumbnail_id_2="1180"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0014.jpeg"
